Xue Li | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Xue Li | Cancer Cell Biology | Best Researcher Award

Dr. Xue Li , Institute of Chemistry Chinses Academy of Sciences , China

Dr. Xue Li is an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, specializing in the design and application of functional carbon nanomaterials in biomedical fields. She holds a Bachelor’s degree from Sichuan University (2009-2013) and a PhD from the Institute of Chemistry, Chinese Academy of Sciences (2013-2018). Since 2018, Dr. Li has contributed significantly to the development of nanomaterial-based therapies for various diseases, particularly focusing on cancer, diabetes, and neurodegenerative diseases. Her work is characterized by innovative approaches to developing fullerene-based nanoparticles for therapeutic purposes. Dr. Li has published extensively in high-impact journals and is a recognized leader in her field, collaborating with national and international experts to drive forward the potential of nanomaterials in medicine.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Xue Li stands out for her groundbreaking research on the design and biomedical application of functional carbon nanomaterials, particularly fullerenes, for treating complex diseases. Her work explores innovative therapeutic strategies, such as targeting inflammation, oxidative stress, and immune responses to address conditions like cancer, diabetes, and neurodegenerative diseases. Dr. Li has authored multiple high-impact journal publications, demonstrating her deep expertise in nanomaterials and their integration into medical treatments. Her contributions, such as reducing neuroinflammation to alleviate Parkinson’s disease and mitigating immune-mediated liver injury, showcase her ability to translate scientific knowledge into real-world solutions. Dr. Li’s collaborative approach and her role in advancing nanomedicine highlight her as a leading figure in her field.

Areas for Improvement:

While Dr. Li’s work is exceptional, expanding her research into more diverse therapeutic areas, such as cardiovascular diseases or neurodegenerative conditions like Alzheimer’s, could further broaden the impact of her research. Additionally, exploring the scalability and commercialization of her nanomaterial-based therapies would be a valuable direction for future development.

Education:

Dr. Xue Li completed her Bachelor’s degree in Chemistry at Sichuan University in June 2013. She pursued her Ph.D. at the Institute of Chemistry, Chinese Academy of Sciences, from 2013 to 2018, focusing on the design and application of nanomaterials, particularly fullerenes, for medical applications. During her doctoral studies, she gained significant experience in the synthesis, functionalization, and biomedical use of carbon nanomaterials. Dr. Li’s research laid the foundation for her current work as an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, a position she has held since 2018.

Experience:

Dr. Xue Li has worked extensively in the field of nanomaterials, contributing to significant advancements in the application of fullerene-based nanoparticles for biomedical purposes. Since 2018, she has been an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, where her research focuses on the development of functional nanomaterials for the treatment of diseases such as cancer, diabetes, and neurodegenerative disorders. Dr. Li has worked on several high-impact projects, including designing inflammation-targeting nanoparticles and investigating their roles in regulating immune responses and improving disease outcomes. Her experience spans both experimental techniques in nanomaterial synthesis and in vivo therapeutic applications. Additionally, Dr. Li has collaborated with multiple research institutions globally and has been recognized for her contributions to advancing nanomedicine.

Research Focus:

Dr. Xue Li’s research focuses on the design, synthesis, and biomedical applications of functional carbon nanomaterials, particularly fullerenes and their derivatives. Her work aims to develop innovative therapeutic strategies, leveraging the unique properties of these nanomaterials to address complex medical challenges, including cancer, autoimmune diseases, and neurodegenerative disorders. She is particularly interested in creating nanoparticles that target specific cellular pathways, such as inflammation and oxidative stress, to improve therapeutic outcomes. Dr. Li’s research includes the development of nanoparticles that can modulate macrophage differentiation and mitigate conditions like rheumatoid arthritis, autoimmune hepatitis, and neuroinflammation. By focusing on the functionalization of fullerenes, her work also explores how these materials can be used to treat insulin resistance and neurodegenerative diseases such as Parkinson’s.

Publications Top Notes:

  1. 🧬 Fullerenols hijack lysosomes to disrupt inter-organellar crosstalk and block autophagy pre-activated by mTOR inhibitors for cancer cell PANoptosis. Sci. Bull. 2025
  2. 💊 Inflammation-targeting fullerene nanoparticles dually inhibit macrophage and osteoclast differentiation for mitigating rheumatoid arthritis. CCS Chem. 2024
  3. 🔬 Curdlan decorated fullerenes mitigate immune-mediated hepatic injury for autoimmune hepatitis therapeutics via reducing macrophage infiltration. ACS Appl. Mater. Interfaces 2024
  4. 💡 The application of nanomaterials in the treatment of pancreatic-related diseases. Int. J. Mol. Sci. 2024
  5. 🧠 Oral [60] fullerene reduces neuroinflammation to alleviate Parkinson’s disease via regulating gut microbiome. Theranostics 2023
  6. 🍏 Dual regulation on oxidative stress and endoplasmic reticulum stress by [70] fullerenes for reversing insulin resistance in diabetes. Nano Today 2022
  7. 🔬 Gadofullerene Nanoparticles Extend Survival Rate and Down-Regulate Thrombin Expression in Orthotopic Pancreatic Cancer. Sci. China Mater. 2022
  8. 🩸 Gadofullerene Nanoparticles Reverse Dysfunctions of Pancreas and Improve Hepatic Insulin Resistance for Type 2 Diabetes Mellitus Treatment. ACS Nano 2019
  9. 🌱 Biomaterials: Application of Nanomaterials in the Treatment of Pancreatic-Related Diseases. Biomaterials 2018

Conclusion:

Dr. Xue Li’s exceptional research on functional nanomaterials and their applications in medicine, particularly in cancer, autoimmune diseases, and neurodegeneration, makes her a strong contender for the Research for Best Researcher Award. Her innovative approaches, contributions to high-impact journals, and dedication to advancing nanomedicine provide a solid foundation for future breakthroughs.

Huining He | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Huining He | Cancer Cell Biology | Best Researcher Award

Prof. Huining He , School of Biomedical Engineering and Technology, Tianjin Medical University , China

Dr. Huining He is a prominent Professor and the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, China. With a Ph.D. in Chemical Engineering from Tianjin University, she completed joint research at the University of Michigan. Her career spans across significant achievements in biomedical engineering, specializing in biomaterials, drug delivery systems, and cancer therapy. She has been recognized with prestigious awards, including the “Young Changjiang Scholar” and the “Tianjin Science Fund for Outstanding Young Scholars.” As an active member of various academic societies and a board member of the Asian Journal of Pharmaceutical Sciences, she fosters international collaboration and academic advancement. Her research has garnered substantial contributions to the field of biomedical engineering, with numerous patents and high-impact publications in cancer treatment and drug delivery systems.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Huining He is an outstanding researcher with a strong academic and professional background. As a Professor and Dean at Tianjin Medical University, she leads the School of Biomedical Engineering and Technology with a focus on cutting-edge biomedical research, particularly in biomaterials and drug delivery systems. Her innovative work in the development of enzyme-sensitive targeted systems for gene therapy and prodrug-type macromolecular drug delivery for colon cancer is a key contribution to the field. Additionally, her leadership in several projects funded by the National Natural Science Foundation of China, particularly those targeting glioma treatment, showcases her ability to translate research into impactful clinical applications.

Dr. He’s collaboration with international and domestic institutions further enhances her research impact. She is well-regarded for pioneering novel drug delivery systems and has made notable contributions through numerous high-quality publications, which have earned her an H-index of 21 and six authorized patents. She also actively participates in academic exchanges and professional networks, serving as a member of editorial boards and scientific committees.

Areas for Improvements:

While Dr. He has made remarkable strides in biomedical engineering, there are areas where further focus could amplify her impact:

  1. Broader Clinical Application: The continued translation of her drug delivery systems into clinical settings could benefit from additional industry partnerships and clinical trials.
  2. Interdisciplinary Collaboration: Expanding her work to incorporate emerging fields such as artificial intelligence in drug delivery systems could lead to more personalized treatment solutions.
  3. Public Engagement: Increasing public awareness of her research through media and outreach could bridge the gap between academia and the general public, facilitating broader societal impact.

Education:

Dr. Huining He earned her Ph.D. in Chemical Engineering from Tianjin University, where she gained profound expertise in biomaterials and drug delivery systems. During her doctoral studies, she participated in joint training at the University of Michigan, an experience that greatly expanded her research skills and international perspective. This training allowed her to engage in cutting-edge projects in the fields of biomaterials and drug delivery. Her advanced education laid the foundation for her future contributions to biomedical engineering, especially in the development of novel targeted systems for gene therapy and cancer treatment. Dr. He’s academic journey has been marked by strong mentorship, international collaborations, and her leadership role in several research projects that have significantly advanced the biomedical field.

Experience:

Dr. Huining He’s career in biomedical engineering spans extensive academic and research experience. Currently, as the Dean of the School of Biomedical Engineering and Technology at Tianjin Medical University, she leads a dynamic department focused on advancing healthcare solutions through innovative research. She has supervised numerous Ph.D. students, guiding them in pioneering research on biomaterials and drug delivery systems. Her work has been recognized by the Ministry of Education, with prestigious titles such as the “Young Changjiang Scholar.” Dr. He has led and contributed to several high-profile research projects funded by China’s National Natural Science Foundation, including investigations into enzyme-sensitive targeted systems for gene therapy and glioma treatment. Beyond academia, she has participated in industry projects, translating her research into real-world applications. As a member of numerous professional organizations and editorial boards, Dr. He plays a vital role in facilitating international collaborations and advancing scientific knowledge in the biomedical sector.

Research Focus:

Dr. Huining He’s research focuses on the design and development of advanced biomaterials and drug delivery systems, particularly in the treatment of cancer and other serious diseases. Her work involves creating innovative, targeted drug delivery systems that can enhance the efficacy and precision of treatment. She has conducted pivotal studies on enzyme-sensitive targeted systems for gene therapy, improving the delivery of therapeutic agents to cancer cells. Currently, Dr. He is leading several projects on siRNA co-delivery systems for glioma, investigating ways to overcome the challenges in glioma treatment. Her research also covers the development of prodrug-type macromolecular systems and multifunctional exosome-based drug delivery technologies. Dr. He’s work has the potential to revolutionize cancer treatment and other therapeutic approaches, contributing to the development of more efficient, less toxic therapies for patients. Her research continues to make substantial advancements in the fields of drug delivery, biomedical engineering, and cancer therapy.

Publications Top Notes:

  1. CaCO3-based nanomedicine with multi-functions of ferroptosis-apoptosis and microenvironment regulation in cancer 🔬💡 (Nano Today, 2025)
  2. Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation 🧬⚡ (ACS Nano, 2024)
  3. Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy 💊🧪 (Chinese Chemical Letters, 2024)
  4. A review on gold nanoparticles as an innovative therapeutic cue in bone tissue engineering: Prospects and future clinical applications 🏥🔬 (Materials Today Bio, 2024)
  5. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment 🧬🔗 (Journal of Controlled Release, 2024)
  6. An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma 💉🧠 (Acta Pharmaceutica Sinica B, 2023)
  7. Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles 🧬💥 (Acta Pharmaceutica Sinica B, 2023)
  8. Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence 💧⚔ (Journal of Controlled Release, 2022)
  9. Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation 🧬💉 (Medicine in Drug Discovery, 2022)
  10. mRNA vaccines for COVID-19 and diverse diseases 💉🦠 (Journal of Controlled Release, 2022)

Conclusion:

Dr. Huining He’s exceptional contributions to the field of biomedical engineering, particularly in the development of novel drug delivery systems for cancer treatment, position her as an ideal candidate for the Best Researcher Award. Her innovative work, combined with a clear vision for the future of precision medicine, continues to drive the field forward. She has the potential to further revolutionize medical treatments, making her a deserving nominee for this prestigious recognition.